Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells 400 Shares of Company Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, October 30th. The stock was sold at an average price of $900.00, for a total transaction of $360,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at $542,700. The trade was a 39.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathryn Guarini also recently made the following trade(s):

• On Wednesday, September 2nd, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00.
• On Monday, August 10th, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $800.00, for a total value of $320,000.00.

Regeneron Pharmaceuticals Stock Up 1.3%

Shares of NASDAQ:REGN traded up $12.10 on Tuesday, reaching $973.36. The company had a trading volume of 1,198,078 shares, compared to its average volume of 828,291. The firm’s 50 day simple moving average is $795.85 and its 200-day simple moving average is $739.07. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $975.49. The firm has a market capitalization of $100.21 billion, a PE ratio of 21.49, a PEG ratio of 1.37 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same period last year, the business earned $11.83 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 36.3% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Orbimed Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth $11,358,000. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $5,682,636,000. Contravisory Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $6,327,000. Oxbow Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $3,342,000. Finally, Deutsche Bank AG purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $323,249,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported Q3 revenue of $5.12 billion, up 36.3% year over year and above expectations of $4.58 billion. EPS of $20.07 also topped the $16.51 consensus. The beat and strength in core commercial products underpin the bullish reaction. Q3 results and pipeline progress
• Positive Sentiment: Multiple firms lifted their targets following the results. JPMorgan raised its target to $1,050 and maintained an Overweight rating; Guggenheim raised its target to $1,100 and kept a Buy rating. Some analyst forecasts reportedly reached $1,175. Analysts raise forecasts
• Neutral Sentiment: Analyst views are not uniformly bullish. Although several firms raised targets, RBC, Morgan Stanley, Bernstein and others retained market-perform, sector-perform or equal-weight ratings, with some targets below the stock’s recent level—suggesting limited upside in their estimates. RBC assessment of commercial performance
• Neutral Sentiment: CNBC traders named REGN among their “Final Trades” after the strong Q3 report, but the mention does not provide a new company-specific catalyst. CNBC Final Trades

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Sanford C. Bernstein upped their price objective on shares of Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the company a “market perform” rating in a report on Monday. UBS Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $660.00 to $978.00 in a research note on Thursday, October 15th. Citigroup increased their price target on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the company a “neutral” rating in a research note on Friday. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Finally, Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.